Many Americans battling diabetes are turning to a new class of injected drugs that includes blockbusters like Ozempic (semaglutide) and Mounjaro (tirzepatide). But a new study finds half of patients who use these “second line” therapies — a class called GLP-1 RAs — quit them within a year. The main factor: Gastrointestinal issues like nausea, vomiting…  read on >  read on >

The diabetes and weight-loss drug Ozempic does not appear to harm a developing fetus when taken by pregnant women, a new study reports. Researchers found no elevated risk of birth defects among newborns of women who took medications to control their type 2 diabetes, compared with those who took insulin. During the decade-long study, researchers…  read on >  read on >

Folks who take the blockbuster weight-loss med tirzepatide (Zepbound) may regain much of the weight they lost soon after discontinuing it, new research shows. A trial funded by Eli Lilly, the injected drug’s maker, found that “in patients with obesity or overweight, withdrawing tirzepatide led to substantial regain of weight.” On the other hand, continuing…  read on >  read on >

Loss of the “happiness” brain hormone serotonin might play a role in the decline of brain function as a person ages, a new study reports. People with mild cognitive impairment (MCI) had up to 25% lower levels of serotonin than healthy people in key regions of the brain associated with memory, problem-solving and emotion, researchers…  read on >  read on >